The proteasome - An emerging therapeutic target in cancer

New England Journal of Medicine

Volumn 348, Issue 26, 2003, Pages 2597-2598

  Mitchell, Beverly S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER; CANCER THERAPY; CELL TRANSFORMATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME SPECIFICITY; GASTROINTESTINAL TOXICITY; HUMAN; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; THROMBOCYTOPENIA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; PEPTIDE HYDROLASES; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 0038649638     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp030092     Document Type: Review

References (2)

1. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
2. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.